当前位置:首页 - 行情中心 - 华熙生物(688363) - 财务分析 - 现金流量表

华熙生物

(688363)

  

流通市值:121.88亿  总市值:296.23亿
流通股本:1.98亿   总股本:4.82亿

现金流量表

报告期2024-03-312023-12-312023-09-302023-06-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
销售商品、提供劳务收到的现金1,327,460,537.146,490,585,264.064,437,349,718.243,196,457,200.85
收到的税费返还13,515,649.5966,800,151.2243,221,607.8530,657,535.16
收到其他与经营活动有关的现金39,476,927.09263,109,199.41199,417,949.03162,812,486.38
经营活动现金流入的平衡项目0000
经营活动现金流入小计1,380,453,113.826,820,494,614.694,679,989,275.123,389,927,222.39
购买商品、接受劳务支付的现金352,866,353.821,558,074,935.941,093,174,002.3790,120,624.82
支付给职工以及为职工支付的现金331,849,772.831,236,876,745.72963,570,332.19685,335,899.29
支付的各项税费126,917,029.13617,343,039.97417,277,100.54279,944,975.26
支付其他与经营活动有关的现金533,968,689.832,708,551,691.841,971,078,622.031,448,100,387.79
经营活动现金流出的平衡项目0000
经营活动现金流出小计1,345,601,845.616,120,846,413.474,445,100,057.063,203,501,887.16
经营活动产生的现金流量净额平衡项目0000
经营活动产生的现金流量净额34,851,268.21699,648,201.22234,889,218.06186,425,335.23
二、投资活动产生的现金流量:
取得投资收益收到的现金7,139,138.9613,781,425.087,754,218.366,269,625.62
处置固定资产、无形资产和其他长期资产收回的现金净额-100100-
收到的其他与投资活动有关的现金334,999,740.081,792,565,942.431,462,456,518.271,332,456,518.27
投资活动现金流入的平衡项目0000
投资活动现金流入小计342,138,879.041,806,347,467.511,470,210,836.631,338,726,143.89
购建固定资产、无形资产和其他长期资产支付的现金228,369,744.921,030,331,002.43756,791,260.15564,734,878.13
投资支付的现金128,700,196.7176,206,227.12112,014,223.82107,720,034.17
支付其他与投资活动有关的现金40,013,879.891,212,692,261.43980,002,000850,000,000
投资活动现金流出的平衡项目0000
投资活动现金流出小计397,083,821.512,419,229,490.981,848,807,483.971,522,454,912.3
投资活动产生的现金流量净额平衡项目0000
投资活动产生的现金流量净额-54,944,942.47-612,882,023.47-378,596,647.34-183,728,768.41
三、筹资活动产生的现金流量:
吸收投资收到的现金-57,714,817.5851,717,222.5851,717,222.58
其中:子公司吸收少数股东投资收到的现金-5,999,6005,999,6005,999,600
筹资活动现金流入平衡项目-000
筹资活动现金流入小计-57,714,817.5851,717,222.5851,717,222.58
偿还债务支付的现金104,686,447.4106,362,524.33105,976,918.99105,446,630.04
分配股利、利润或偿付利息支付的现金1,307,371.53305,484,844.04304,225,107.09296,773,258.21
支付其他与筹资活动有关的现金114,211,505.93173,433,945.355,342,859.5534,834,008.36
筹资活动现金流出平衡项目0000
筹资活动现金流出小计220,205,324.86585,281,313.67465,544,885.63437,053,896.61
筹资活动产生的现金流量净额平衡项目0000
筹资活动产生的现金流量净额-220,205,324.86-527,566,496.09-413,827,663.05-385,336,674.03
四、汇率变动对现金及现金等价物的影响-1,528,348.1510,564,999.387,198,775.6514,359,053.67
现金及现金等价物净增加额平衡项目0000
五、现金及现金等价物净增加额-241,827,347.27-430,235,318.96-550,336,316.68-368,281,053.54
加:期初现金及现金等价物余额813,059,9821,243,295,300.961,243,295,300.961,243,295,300.96
期末现金及现金等价物余额平衡项目0000
期末现金及现金等价物余额571,232,634.73813,059,982692,958,984.28875,014,247.42
补充资料:
净利润-582,742,033.51-421,561,907.33
资产减值准备-54,403,392.42-210,691.87
固定资产和投资性房地产折旧-184,254,800.77-89,542,953.94
其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-184,254,800.77-89,542,953.94
无形资产摊销-21,053,043.69-9,932,540.04
长期待摊费用摊销-27,737,964.24-13,358,233
处置固定资产、无形资产和其他长期资产的损失-3,424,302.25--
固定资产报废损失-1,872,263.58-1,090
公允价值变动损失--1,467,665.76--260,750
财务费用-8,173,679.32--7,796,189.35
投资损失--1,327,375.89--1,597,280.23
递延所得税--34,959,083.2--29,858,930.88
其中:递延所得税资产减少--34,391,487.93--29,211,218.48
递延所得税负债增加--567,595.27--647,712.4
存货的减少-13,883,762.91--6,471,484.86
经营性应收项目的减少-54,482,014.55--106,047,117.53
经营性应付项目的增加--321,535,537.99--261,472,180.33
其他-42,501,632.68-25,635,124.69
不涉及现金收支的投资和筹资活动金额其他项目-63,923,114.69--
现金的期末余额-813,059,982-875,014,247.42
减:现金的期初余额-1,243,295,300.96-1,243,295,300.96
公告日期2024-04-302024-04-302023-10-312023-08-30
审计意见(境内)标准无保留意见
TOP↑